We are live on ! Find out more
TRCT

Tower Research Capital (TRC) Portfolio holdings

AUM $3.85B
1-Year Est. Return 32.11%
This Fund
S&P 500
This Quarter Est. Return
-1.75%
1 Year Est. Return
+32.11%
3 Year Est. Return
+93.86%
5 Year Est. Return
+112.79%
10 Year Est. Return
+380.9%
AUM
$892M
AUM Growth
+$114M
Cap. Flow
+$142M
Cap. Flow %
15.87%
Top 10 Hldgs %
24.46%
Holding
5,559
New
1,359
Increased
1,658
Reduced
1,483
Closed
897

Sector Composition

Rank Sector Weight
1 Technology 9.8%
2 Healthcare 7.16%
3 Financials 6.42%
4 Consumer Discretionary 4.97%
5 Communication Services 4.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
QCLS
4151
Q/C Technologies Inc
QCLS
$22.9M
0
GPUS
4152
Hyperscale Data Inc
GPUS
$55.4M
0
AIFU
4153
AIFU Inc
AIFU
$221M
0
PSIX
4154
Power Solutions International
PSIX
$942M
$1K ﹤0.01%
16
-694
-98% -$47K
TVRD
4155
Tvardi Therapeutics
TVRD
$23.4M
$1K ﹤0.01%
+4
New +$1.64K
VOXX
4156
DELISTED
VOXX International Corporation Class A
VOXX
$1K ﹤0.01%
100
-31
-24% -$301
BCOV
4157
DELISTED
Brightcove, Inc.
BCOV
$1K ﹤0.01%
214
-742
-78% -$5.22K
WHLM
4158
DELISTED
Wilhelmina International, Inc
WHLM
$1K ﹤0.01%
+116
New +$725
TELL
4159
DELISTED
Tellurian Inc.
TELL
$1K ﹤0.01%
52
+50
+2,500% +$810
VGR
4160
DELISTED
Vector Group Ltd.
VGR
$1K ﹤0.01%
77
-764
-91% -$8.96K
HOLI
4161
DELISTED
Hollsys Automation Technologies INTERNATIONAL, LTD. COMMON (British Virgin Island)
HOLI
$1K ﹤0.01%
71
-40
-36% -$898
DLA
4162
DELISTED
Delta Apparel Inc.
DLA
$1K ﹤0.01%
149
-54
-27% -$605
NURO
4163
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
0
EIGR
4164
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
-1
Closed -$5.28K
ONCT
4165
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$1K ﹤0.01%
+1
New +$1.47K
PACW
4166
DELISTED
PacWest Bancorp
PACW
$1K ﹤0.01%
27
-13,157
-100% -$552K
FRGI
4167
DELISTED
Fiesta Restaurant Group, Inc.
FRGI
$1K ﹤0.01%
+19
New +$903
INFI
4168
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1K ﹤0.01%
+100
New +$1.19K
WTT
4169
DELISTED
Wireless Telecom Group, Inc.
WTT
$1K ﹤0.01%
315
SPPI
4170
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$1K ﹤0.01%
100
-2,957
-97% -$23.1K
OFED
4171
DELISTED
Oconee Federal Financial Corp.
OFED
$1K ﹤0.01%
81
-315
-80% -$5.57K
LD
4172
DELISTED
iPath Bloomberg Lead Subindex Total Return ETN due June 24, 2038
LD
$1K ﹤0.01%
+14
New +$691
SNMP
4173
DELISTED
Evolve Transition Infrastructure LP
SNMP
$1K ﹤0.01%
1
BIOC
4174
DELISTED
Biocept, Inc.
BIOC
0
DDF
4175
DELISTED
Delaware Investments Dividend & Income Fund, Inc.
DDF
$1K ﹤0.01%
100
-100
-50% -$1.01K

Similar funds

Tower Research Capital (TRC)'s Q3 2014 Portfolio in Review

As of Q3 2014, Tower Research Capital (TRC) held 5,559 positions worth $892M, up 15% from $778M the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Tower Research Capital (TRC) deployed $142M of net new capital in Q3 2014, opening 1,359 new positions and adding to 1,658 existing holdings. Its largest new stake was State Street SPDR S&P Oil & Gas Exploration & Production ETF: 35,647 shares worth $9.81M.

By sector, the portfolio is most concentrated in Technology at 9.8% of assets, up from 5.2% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $106M trimmed.

  • Tower Research Capital (TRC)'s largest Q3 2014 buy was State Street SPDR S&P Oil & Gas Exploration & Production ETF: 35,647 shares worth $9.81M.
  • Tower Research Capital (TRC) added most to iShares Russell 2000 ETF in Q3 2014, an estimated $23.8M increase.
  • Tower Research Capital (TRC)'s biggest Q3 2014 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $106M.
  • Tower Research Capital (TRC) fully exited iShares Russell 1000 Value ETF in Q3 2014, selling an estimated $9.03M.
  • Tower Research Capital (TRC)'s ten largest holdings make up 24% of its $892M portfolio in Q3 2014.
  • Tower Research Capital (TRC) opened 1,359 new positions and closed 897 in Q3 2014.
  • Tower Research Capital (TRC)'s portfolio value rose 15% quarter-over-quarter to $892M.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2014, filed 31 Oct 2014.